Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥18~* Essential hypertension: systolic blood pressure (SBP) is between 140mmHg-179mmHg and diastolic blood pressure (DBP)\<110mmHg OR DBP is between 90mmHg-109mmHg and SBP\<180mmHg.~* Hypertension patients diagnosed by spot urine test (urine sodium≥200mmol/24h).~* Subjects are not using antihypertensive medicines or medicines which affect the blood pressure within a week.~* Subjects volunteer to be brought in the research and have signed informed consent form, given that they have understood the research content.~Exclusion Criteria:~* Females who are already pregnant, in lactation and intend to be pregnant.~* Patients who have seriously allergic reaction or angioneurotic edema when taking ARB; Patients who have allergic history of thiazide diuretic (HCTZ) or sulfonamides.~* Patients who do not want to stop or have to take the medicines which are also antihypertensive or affect the blood pressure, other than which provided by the research.~* Stroke or CHD patients who are diagnosed within 6 months. CHD patients are identified by being diagnosed by coronary arteriography or coronary CT angiography, having received coronary stent or coronary artery bypass surgery, or being diagnosed with acute myocardial infarction. Stroke patients are identified by being diagnosed with cerebral thrombosis, cerebral embolism, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack.~* Patients who are clearly diagnosed with following diseases: Congenital disease, myocardiopathy, serious arrhythmia, pulmonary heart disease, various of cardiac failure.~* Patients who are clearly diagnosed with following symptoms or diseases: Proteinuria or heavy proteinuria, renal insufficiency or serious renal function damage, hepatic insufficiency or serious hepatic function damage; retinal exudates or hemorrhage, or papilledema.~* Patients who are clearly diagnosed with serious or deadly diseases in other systems.~* Patients who get dementia or other serious diseases cannot cooperate with researchers.~* Patients who drink 200g white spirits per day in past week.~* Patients who meet other situations which are considered to be inappropriate to be enrolled into the study by researchers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan (Type: EXPERIMENTAL): capsule,40mg per day,2 months
- Hydrochlorothiazide (Type: EXPERIMENTAL): tablet, 25mg per day, 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).